Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products

References

• Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N EngI J Med 2001; 344: 1031–1037
   PubMed Web of Science ®Google Scholar
• O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Cortes J E, O'Brien S, Giles F, Garcia-Manero G, Faderl S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101: 97–100
   PubMed Web of Science ®Google Scholar
• Press R D, Love Z, Tronnes A A, Yang R, Tran T, Mongoue-Tchokote S, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006; 107: 4250–4256
   PubMed Web of Science ®Google Scholar
• Reiffers J, Goldman J, Meloni G, Cahn J Y, Gratwohl A. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant 1994; 14: 407–410
   PubMed Web of Science ®Google Scholar
• Deisseroth A B, Zu Z, Claxton D, Hanania E G, Fu S, Ellerson D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068–3076
   PubMed Web of Science ®Google Scholar
• Martinelli G, Montefusco V, Amabile M, Lemoli R M, Terragna C, Testoni N, et al. Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response. Leuk Lymphoma 2000; 39: 113–120
   PubMed Web of Science ®Google Scholar
• Gordon M K, Kebriaei P, Sher D, Bennett D, Larson R A, Stock W. Autologous stem cell collection and measurement of minimal residual disease in patients with chronic myeloid leukemia (CML) treated with imatinib mesylate. Blood (Suppl.) 2003; 102: 953a
   PubMed Web of Science ®Google Scholar
• Stock W, Yu D, Karrison T, Sher D, Stone R M, Larson R A, et al. Quantitative real time RT-PCR monitoring of BCR-ABL in CML shows lack of agreement in blood and bone marrow samples: Cancer and Leukemia Group B study 29801. Int J Oncol 2006; 28: 1099–1103
   PubMed Web of Science ®Google Scholar
• Beillard E, Pallisgaard N, van der Velden V H, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program. Leukemia 2003; 17: 2474–2486
   PubMed Web of Science ®Google Scholar
• Agis H, Jaeger E, Doninger B, Sillaber C, Marosi C, Drach J, et al. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells. Eur J Clin Invest 2006; 36: 402–408
   PubMed Web of Science ®Google Scholar
• Hui C H, Goh K Y, White D, Branford S, Grigg A, Seymour J F, et al. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia 2003; 17: 821–828
   PubMed Web of Science ®Google Scholar
• Drummond M W, Marin D, Clark R E, Byrne J L, Holyoake T L, Lennard A. Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol 2003; 123: 479–483
   PubMed Web of Science ®Google Scholar
• Kreuzer K A, Kluhs C, Baskaynak G, Movassaghi K, Dorken B, le Coutre P. Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol 2004; 124: 195–199
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, et al. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res 2006; 12: 3037–3042
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden V H, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah N P, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–2541
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542–2551
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908–916
   PubMed Web of Science ®Google Scholar
• Wetzler M, Stock W, Owzar K, Sher D A, Hoke E E, Linker C A, et al. Sequential imatinib and chemotherapy yield reverse-transcriptase polymerase chain reaction (RT-PCR)-negative peripheral stem cell collections in Philadelphia (Ph) chromosome positive acute lymphoblastic leukemia (ALL) – preliminary results of CALGB 10001. J Clin Oncol ASCO Ann Meet Proc 2006; 24: 6549, (abstract)
   Google Scholar
• Ferrara F, Palmieri S, Annunziata M, Pocali B, Viola A, Pane F. Prolonged molecular remission after autologous stem cell transplantation in relapsed acute promyelocytic leukemia. Haematologica 2004; 89: 621–622
   PubMed Web of Science ®Google Scholar